Monoclonal antibody inhibitors of EGFR have been developed for cancer therapy in the last two decades, including cetuximab and necitumumab approved by the U.S. Food and Drug Administration (FDA) for lung adenocarcinoma (LUAD) and squamous cell lung cancer (5, 6), and panitumumab and cetuximab approved by the FDA and European Medicines Agency (EMA) for the treatment of metastatic CRC (7). Here, EGFR is linked to cancer.